{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:06:20Z","timestamp":1792292780499,"version":"4.4.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,9,14]],"date-time":"2012-09-14T00:00:00Z","timestamp":1347580800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s00192-012-1915-8","type":"journal-article","created":{"date-parts":[[2012,9,13]],"date-time":"2012-09-13T11:48:21Z","timestamp":1347536901000},"page":"595-604","source":"Crossref","is-referenced-by-count":34,"title":["Oxybutynin: past, present, and future"],"prefix":"10.1007","volume":"24","author":[{"given":"Kelly","family":"Jirschele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter K.","family":"Sand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,9,14]]},"reference":[{"key":"1915_CR1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00192-009-0976-9","volume":"21","author":"BT Haylen","year":"2010","unstructured":"Haylen BT, de Ridder D, Freeman RM et al (2010) An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 21:5\u201326","journal-title":"Int Urogynecol J"},{"key":"1915_CR2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","volume":"20","author":"WF Stewart","year":"2003","unstructured":"Stewart WF, Van Rooyen JB, Cundiff GW et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327\u2013336","journal-title":"World J Urol"},{"key":"1915_CR3","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","volume":"87","author":"I Milsom","year":"2001","unstructured":"Milsom I, Abrams P, Cardozo L et al (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87:760\u2013766","journal-title":"BJU Int"},{"key":"1915_CR4","first-page":"S580","volume":"6","author":"P Abrams","year":"2000","unstructured":"Abrams P, Kelleher CJ, Kerr LA, Rogers RG (2000) Overactive bladder significantly affects quality of life. Am J Manag Care 6:S580\u2013S590","journal-title":"Am J Manag Care"},{"key":"1915_CR5","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0090-4295(01)00986-4","volume":"57","author":"JN Liberman","year":"2001","unstructured":"Liberman JN, Hunt TL, Stewart WF et al (2001) Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology 57:1044\u20131050","journal-title":"Urology"},{"key":"1915_CR6","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/01.jom.0000161744.21780.c1","volume":"47","author":"EQ Wu","year":"2005","unstructured":"Wu EQ, Birnbaum H, Marynchenko M et al (2005) Employees with overactive bladder: work loss burden. J Occup Environ Med 47:439\u2013446","journal-title":"J Occup Environ Med"},{"key":"1915_CR7","first-page":"43","volume":"96","author":"TW Hu","year":"2005","unstructured":"Hu TW, Wagner TH (2005) Health-related consequences of overactive bladder: an economic perspective. BJU Int 96:43\u201345","journal-title":"BJU Int"},{"key":"1915_CR8","first-page":"S44","volume":"4","author":"J Voytas","year":"2002","unstructured":"Voytas J (2002) The role of geriatricians and family practitioners in the treatment of overactive bladder and incontinence. Rev Urol 4:S44\u2013S49","journal-title":"Rev Urol"},{"key":"1915_CR9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0090-4295(97)00587-6","volume":"50","author":"WC Groat de","year":"1997","unstructured":"de Groat WC (1997) A neurologic basis for the overactive bladder. Urology 50:36\u201352","journal-title":"Urology"},{"key":"1915_CR10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0090-4295(97)00591-8","volume":"50","author":"AF Brading","year":"1997","unstructured":"Brading AF (1997) A myogenic basis for the overactive bladder. Urology 50:57\u201367","journal-title":"Urology"},{"key":"1915_CR11","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/00003081-200203000-00020","volume":"45","author":"RP Goldberg","year":"2002","unstructured":"Goldberg RP, Sand PK (2002) Pathophysiology of the overactive bladder. Clin Obstet Gynecol 45:182\u2013192","journal-title":"Clin Obstet Gynecol"},{"key":"1915_CR12","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1097\/01.ju.0000142429.59753.5c","volume":"172","author":"JJ Wyndaele","year":"2004","unstructured":"Wyndaele JJ, Van Meel TD, De Wachter S (2004) Detrusor overactivity. Does it represent a difference if patients feel the involuntary contractions? J Urol 172:1915\u20131918","journal-title":"J Urol"},{"key":"1915_CR13","doi-asserted-by":"crossref","first-page":"F489","DOI":"10.1152\/ajprenal.00467.2004","volume":"289","author":"LA Birder","year":"2005","unstructured":"Birder LA (2005) More than just a barrier: urothelium as a drug target for urinary bladder pain. Am J Physiol Renal Physiol 289:F489\u2013F495","journal-title":"Am J Physiol Renal Physiol"},{"key":"1915_CR14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2217\/14750708.3.2.215","volume":"3","author":"PK Sand","year":"2006","unstructured":"Sand PK (2006) Trospium chloride: over 20\u00a0years of clinical use. Therapy 3:215\u2013226","journal-title":"Therapy"},{"key":"1915_CR15","first-page":"467","volume":"156","author":"PM Lish","year":"1965","unstructured":"Lish PM, Labudde JA, Peters EL, Robbins SI (1965) Oxybutynin\u2014a musculotropic antispasmodic drug with moderate anticholinergic action. Arch Int Pharmacodyn Ther 156:467\u2013488","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"1915_CR16","first-page":"284","volume":"6","author":"ME Rossman","year":"1964","unstructured":"Rossman ME, Merlis S (1964) A clinical evaluation of oxybutynin chloride in the treatment of gastrointestinal disease. Curr Ther Res Clin Exp 6:284\u2013289","journal-title":"Curr Ther Res Clin Exp"},{"key":"1915_CR17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0022-5347(17)60721-3","volume":"108","author":"AC Diokno","year":"1972","unstructured":"Diokno AC, Lapides J (1972) Oxybutynin: a new drug with analgesic and anticholinergic properties. J Urol 108:307\u2013309","journal-title":"J Urol"},{"issue":"1","key":"1915_CR18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.7257\/1053-816X.2010.30.1.29","volume":"30","author":"P Ellsworth","year":"2010","unstructured":"Ellsworth P, Kirshenbaum E (2010) Update on the pharmacologic management of overactive bladder: the present and the future. Urol Nurs 30(1):29\u201338, 53","journal-title":"Urol Nurs"},{"key":"1915_CR19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2165\/00002512-199506030-00007","volume":"6","author":"YE Yarker","year":"1995","unstructured":"Yarker YE, Goa KL, Fitton A (1995) Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 6:243\u2013262","journal-title":"Drugs Aging"},{"key":"1915_CR20","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0022-5347(01)65148-6","volume":"157","author":"K Waldeck","year":"1997","unstructured":"Waldeck K, Larsson B, Andersson K-E (1997) Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol 157:1093\u20131097","journal-title":"J Urol"},{"key":"1915_CR21","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3109\/00498259209053145","volume":"22","author":"KM Hughes","year":"1992","unstructured":"Hughes KM, Lang CT, Lazare R et al (1992) Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica 22:859\u2013869","journal-title":"Xenobiotica"},{"key":"1915_CR22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0022-5347(17)41482-0","volume":"140","author":"JG Ouslander","year":"1988","unstructured":"Ouslander JG, Blaustein J, Connor A et al (1988) Pharmacokinetics and clinical effects of oxybutynin in geriatric patients. J Urol 140:47\u201350","journal-title":"J Urol"},{"key":"1915_CR23","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0022-3565(25)13294-1","volume":"247","author":"JF Kachur","year":"1988","unstructured":"Kachur JF, Peterson JS, Carter JP et al (1988) R and S enantiomers of oxybutynin: pharmacological effects in guinea pig bladder and intestine. J Pharmacol Exp Ther 247:867\u2013872","journal-title":"J Pharmacol Exp Ther"},{"key":"1915_CR24","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0022-5347(17)47191-6","volume":"134","author":"L Nilvebrant","year":"1985","unstructured":"Nilvebrant L, Andersson K-E, Mattiasson A (1985) Characterization of the muscarinic cholinoceptors in the human detrusor. J Urol 134:418\u2013423","journal-title":"J Urol"},{"key":"1915_CR25","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/BF00558247","volume":"35","author":"J Douchamps","year":"1988","unstructured":"Douchamps J, Derenne F, Stockis A et al (1988) The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol 35:515\u2013520","journal-title":"Eur J Clin Pharmacol"},{"key":"1915_CR26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0014-2999(86)90697-7","volume":"123","author":"L Nilvebrant","year":"1986","unstructured":"Nilvebrant L, Sparf B (1986) Dicyclomine, benzhexol and oxybutynin distinguish between subclasses of muscarinic binding sites. Eur J Pharmacol 123:133\u2013143","journal-title":"Eur J Pharmacol"},{"key":"1915_CR27","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S0022-3565(25)23176-7","volume":"256","author":"L Norhona-Blob","year":"1991","unstructured":"Norhona-Blob L, Kachur JF (1991) Enantiomers of oxybutynin: in vitro pharmacological characterization at M1, M2 and M3 muscarinic receptors and in vivo effects on urinary bladder contraction, mydriasis and salivary secretion in guinea pigs. J Pharmacol Exp Ther 256:562\u2013567","journal-title":"J Pharmacol Exp Ther"},{"key":"1915_CR28","first-page":"12","volume":"12","author":"MJ Kennelly","year":"2010","unstructured":"Kennelly MJ (2010) A comparative review of oxybutynin chloride formulations: pharmacokinetics and therapeutic efficacy in overactive bladder. Rev Urol 12:12\u201319","journal-title":"Rev Urol"},{"key":"1915_CR29","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0022-5347(17)38459-8","volume":"145","author":"JW Th\u00fcroff","year":"1991","unstructured":"Th\u00fcroff JW, Bunke B, Ebner A et al (1991) Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol 145:813\u2013817","journal-title":"J Urol"},{"key":"1915_CR30","first-page":"5","volume":"27","author":"G Amarenco","year":"1998","unstructured":"Amarenco G, Marquis P, McCarthy C et al (1998) Qualit\u00e9 de vie des femmes souffrant d\u2019mp\u00e9riosit\u00e9 mictionelle avec ou sans fuites: \u00e9tude prospective apr\u00e9s traitement par oxybutynine (1701 cas). Presse Med 27:5\u201310","journal-title":"Presse Med"},{"key":"1915_CR31","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/sc.1996.51","volume":"34","author":"SM Szoller","year":"1996","unstructured":"Szoller SM, Lee SM (1996) Intravesical oxybutynin for spinal cord injury patients. Spinal Cord 34:284\u2013287","journal-title":"Spinal Cord"},{"key":"1915_CR32","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/S0022-5347(01)68161-8","volume":"158","author":"YH Kim","year":"1997","unstructured":"Kim YH, Bird ET, Priebe M et al (1997) The role of oxybutynin in spinal cord injured patients with indwelling catheters. J Urol 158:2083\u20132086","journal-title":"J Urol"},{"key":"1915_CR33","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1464-410X.1988.tb04356.x","volume":"62","author":"RJ Baigrie","year":"1988","unstructured":"Baigrie RJ, Kelleher JP, Fawcett DP et al (1988) Oxybutynin: is it safe? Br J Urol 62:319\u2013322","journal-title":"Br J Urol"},{"key":"1915_CR34","first-page":"389","volume":"47","author":"AP Jonville","year":"1992","unstructured":"Jonville AP, Dutertre JP, Autret E et al (1992) Effets ind\u00e9sirables du chlorure d\u2019oxybutynine (Ditropan\u00ae). Therapie 47:389\u2013392","journal-title":"Therapie"},{"key":"1915_CR35","unstructured":"Oxybutynin PDR information http:\/\/www.pdr.net\/drugpages\/concisemonograph.aspx?concise=100"},{"key":"1915_CR36","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1532-5415.1995.tb07193.x","volume":"43","author":"JG Ouslander","year":"1995","unstructured":"Ouslander JG, Schnelle JF, Uman G et al (1995) Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents? A placebo-controlled trial. J Am Geriatr Soc 43:610\u2013617","journal-title":"J Am Geriatr Soc"},{"key":"1915_CR37","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/ageing\/24.4.287","volume":"24","author":"G Szonyi","year":"1995","unstructured":"Szonyi G, Collas DM, Ding YY et al (1995) Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. Age Ageing 24:287\u2013291","journal-title":"Age Ageing"},{"key":"1915_CR38","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1365-2125.1996.tb00161.x","volume":"41","author":"RM Hussain","year":"1996","unstructured":"Hussain RM, Hartigan-Go K, Thomas SHL et al (1996) Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence. Br J Clin Pharmacol 41:73\u201375","journal-title":"Br J Clin Pharmacol"},{"key":"1915_CR39","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.juro.2006.06.088","volume":"176","author":"S Tyagi","year":"2006","unstructured":"Tyagi S, Tyagi P, Van-le S, Yoshimura N, Chancellor MB, de Miguel F (2006) Qualitative and quantitative expression profile of muscarinic receptors in human urothelium and detrusor. J Urol 176:1673\u20131678","journal-title":"J Urol"},{"key":"1915_CR40","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/009127009903900313","volume":"39","author":"SK Gupta","year":"1999","unstructured":"Gupta SK, Sathyan G (1999) Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol 39:289\u2013296","journal-title":"J Clin Pharmacol"},{"key":"1915_CR41","doi-asserted-by":"crossref","first-page":"687","DOI":"10.4065\/78.6.687","volume":"78","author":"AC Diokno","year":"2003","unstructured":"Diokno AC, Appell RA, Sand PK et al (2003) Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 78:687\u2013695","journal-title":"Mayo Clin Proc"},{"key":"1915_CR42","doi-asserted-by":"crossref","unstructured":"Appell RA, Sand P, Dmochowski R et al (2001) Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. http:\/\/www.ncbi.nlm.nih.gov.proxy.uchicago.edu\/pubmed\/11322350 Mayo Clin Proc 76:358\u2013363","DOI":"10.1016\/S0025-6196(11)62382-3"},{"key":"1915_CR43","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0022-5347(01)62828-3","volume":"160","author":"G Buyse","year":"1998","unstructured":"Buyse G, Waldeck K, Verpoorten C, Bj\u00f6rk H, Casaer P, Andersson KE (1998) Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. J Urol 160:892\u2013896","journal-title":"J Urol"},{"key":"1915_CR44","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0090-4295(93)90098-U","volume":"41","author":"DL Weese","year":"1993","unstructured":"Weese DL, Roskamp DA, Leach GE, Zimmern PE (1993) Intravesical oxybutynin chloride: experience with 42 patients. Urology 41:527\u2013530","journal-title":"Urology"},{"key":"1915_CR45","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/00005392-199707000-00076","volume":"158","author":"SM Stasi Di","year":"1997","unstructured":"Di Stasi SM, Giannantoni A, Massoud R, Cortese C et al (1997) Electromotive administration of oxybutynin into the human bladder wall. J Urol 158:228\u2013233","journal-title":"J Urol"},{"key":"1915_CR46","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/S0022-5347(05)65540-1","volume":"166","author":"SM Stasi Di","year":"2001","unstructured":"Di Stasi SM, Giannantoni A, Navarra P, Capelli G et al (2001) Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl oxybutynin. J Urol 166:2232\u20132236","journal-title":"J Urol"},{"key":"1915_CR47","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/BF01982217","volume":"9","author":"HA Winkler","year":"1998","unstructured":"Winkler HA, Sand PK (1998) Treatment of detrusor instability with oxybutynin rectal suppositories. Int Urogynecol J Pelvic Floor Dysfunct 9:100\u2013102","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"1915_CR48","first-page":"691","volume":"55","author":"P Radziszewski","year":"2002","unstructured":"Radziszewski P, Borkowski A (2002) Therapeutic effects of intrarectal administration of oxybutynin. Wiad Lek 55:691\u2013698","journal-title":"Wiad Lek"},{"key":"1915_CR49","first-page":"346","volume":"16","author":"D Collas","year":"1997","unstructured":"Collas D, Malone-Lee JG (1997) The pharmacokinetic properties of rectal oxybutynin \u2013 a possible alternative to intravesical administration. Neurourol Urodyn 16:346\u2013350","journal-title":"Neurourol Urodyn"},{"key":"1915_CR50","first-page":"19","volume":"2","author":"RJ McCrery","year":"2006","unstructured":"McCrery RJ, Appell RA (2006) Oxybutynin: an overview of the available formulations. Ther Clin Risk Manag 2:19\u201324","journal-title":"Ther Clin Risk Manag"},{"key":"1915_CR51","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1358\/dot.2010.46.6.1487750","volume":"46","author":"DR Staskin","year":"2010","unstructured":"Staskin DR, Salvatore S (2010) Oxybutynin topical and transdermal formulations: an update. Drugs Today (Barc) 46:417\u2013425","journal-title":"Drugs Today (Barc)"},{"key":"1915_CR52","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00345-005-0012-8","volume":"23","author":"RR Dmochowski","year":"2005","unstructured":"Dmochowski RR, Nitti V, Staskin D, Luber K, Appell R, Davila GW (2005) Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol 23:263\u2013270","journal-title":"World J Urol"},{"key":"1915_CR53","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00019053-200927040-00005","volume":"27","author":"LT Pizzi","year":"2009","unstructured":"Pizzi LT, Talati A, Gemmen E et al (2009) Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study. Pharmacoeconomics 27:329\u2013339","journal-title":"Pharmacoeconomics"},{"key":"1915_CR54","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s11934-009-0053-4","volume":"10","author":"PK Sand","year":"2009","unstructured":"Sand PK (2009) The evolution of transdermal therapy for overactive bladder. Curr Urol Rep 10:338\u2013341","journal-title":"Curr Urol Rep"},{"key":"1915_CR55","unstructured":"Gelnique\u00ae prescribing information. Available via http:\/\/pi.watson.com\/data_streaam.asp?product_group=1634&pi&language=E"},{"key":"1915_CR56","doi-asserted-by":"crossref","unstructured":"Caramelli KE, Staskin DR, Volinn W (2008) Steady-state pharmacokinetics of an investigational oxybutynin topical gel in comparison with oxybutynin transdermal system. Annual Meeting of the American Urological Association, 17\u201322 May 2008, Orlando, abstract 1508","DOI":"10.1016\/S0022-5347(08)61516-5"},{"key":"1915_CR57","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/BF01403842","volume":"30","author":"N Hayashi","year":"1985","unstructured":"Hayashi N, Kamada T, Sato N, Kasahara A, Peterson JA (1985) Inhibition of cytochrome P-450-dependent mixed function oxidation by ethanol. Dig Dis Sci 30:334\u2013339","journal-title":"Dig Dis Sci"},{"key":"1915_CR58","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3109\/03602539009041089","volume":"22","author":"J Kao","year":"1990","unstructured":"Kao J, Carver MP (1990) Cutaneous metabolism of xenobiotics. Drug Metab Rev 22:363\u2013410","journal-title":"Drug Metab Rev"},{"key":"1915_CR59","unstructured":"Caramelli KE, Stanworth S, Volin W, Hoel G (2008) Pharmacokinetics of oxybutynin topical gel: effects of showering, sunscreen application, and person-to-person transference. Annual Meeting of the American Urological Association-Western Section, 26\u201330 October 2008, Monterey, abstract 219"},{"key":"1915_CR60","unstructured":"Caramelli KE, Thomas H, Stanworth S, Hoel G (2008) Steady-state bioavailability of oxybutynin topical gel at 3 different application sites. Annual Senior Care Pharmacy Meeting of the American Society of Consultant Pharmacists, 19\u201322 November 2008, New Orleans, poster"},{"key":"1915_CR61","unstructured":"Staskin DR, Goldfischer ER, Bidair MN, Kaushik JD (2011) A once-daily titratable gel formulation for transdermal oxybutynin delivery for OAB. Annual Meeting of the American Urological Association-Western Section, 21 August 2011, Vancouver, abstract"},{"key":"1915_CR62","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0090-4295(02)02577-3","volume":"61","author":"RM Levin","year":"2003","unstructured":"Levin RM, Whitbeck C, Borow A, Burden O, Leggett RE (2003) Effectiveness of vaginally administered oxybutynin on rabbit bladder function. Urology 61:1273\u20131277","journal-title":"Urology"},{"key":"1915_CR63","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1097\/01.ju.0000092557.02298.da","volume":"171","author":"EC Chou","year":"2004","unstructured":"Chou EC, Whitbeck C, Borow A et al (2004) Inhibition of hyperreflexia by vaginally administered oxybutynin: a novel rabbit model. J Urol 171:958\u2013962","journal-title":"J Urol"},{"key":"1915_CR64","unstructured":"Das AK, Maccarone JL (2001) The Safety, Local Tolerability, Pharmacokinetics, and Risk\/Benefit of Oxybutynin Transvaginal Rings (TVR) in Women with a History of Overactive Bladder. Synopsis -FEI Ph 1 PK Study FEI Technologies, Inc report 22 February 2001"},{"key":"1915_CR65","first-page":"S138","volume":"22","author":"M Gittleman","year":"2011","unstructured":"Gittleman M, Reape KZ, Dasen S, Hait HI (2011) A phase 2 study evaluating the safety and efficacy of two doses of a monthly oxybutynin vaginal ring in women with symptoms of overactive bladder. Int Urogynecol J 22:S138\u2013S139","journal-title":"Int Urogynecol J"},{"key":"1915_CR66","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1755-5949.2011.00248.x","volume":"18","author":"M Chancellor","year":"2012","unstructured":"Chancellor M, Boone T (2012) Anticholinergics for overactive bladder therapy: central nervous system effects. CNS Neurosci Ther 18:167\u2013174","journal-title":"CNS Neurosci Ther"},{"key":"1915_CR67","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF00191165","volume":"47","author":"A Pietzko","year":"1994","unstructured":"Pietzko A, Dimpfel W, Schwantes U, Topfmeier P (1994) Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol 47:337\u2013343","journal-title":"Eur J Clin Pharmacol"},{"key":"1915_CR68","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/00912700122010528","volume":"41","author":"A Todorova","year":"2001","unstructured":"Todorova A, Vonderheid-Guth N, Dimpfel W (2001) Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 41:636\u2013644","journal-title":"J Clin Pharmacol"},{"key":"1915_CR69","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2165\/00044011-200323060-00003","volume":"23","author":"K Diefenbach","year":"2003","unstructured":"Diefenbach K, Donath F, Maurer A et al (2003) Randomized, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers. Clin Drug Investig 23:395\u2013404","journal-title":"Clin Drug Investig"},{"key":"1915_CR70","first-page":"217","volume":"50","author":"K Herberg","year":"1999","unstructured":"Herberg K (1999) Safety in everyday situations and street traffic with the use of medication for incontinence. New investigations into the safety and potential of urological anticholinergic drugs. Med Welt 50:217\u2013222","journal-title":"Med Welt"},{"key":"1915_CR71","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.eururo.2006.03.057","volume":"50","author":"G Kay","year":"2006","unstructured":"Kay G, Crook T, Rekeda L et al (2006) Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 50:317\u2013326","journal-title":"Eur Urol"},{"key":"1915_CR72","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1532-5415.2008.01680.x","volume":"56","author":"TE Lackner","year":"2008","unstructured":"Lackner TE, Wyman JF, McCarthy TC, Monigold M, Davey C (2008) Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. J Am Geriatr Soc 56:862\u2013870","journal-title":"J Am Geriatr Soc"},{"key":"1915_CR73","unstructured":"Ditropan\u00ae (package insert). Ortho-McNeil-Janssen Pharmaceuticals, Inc., Raritan, June 2011"}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-012-1915-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00192-012-1915-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-012-1915-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T12:50:13Z","timestamp":1744116613000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00192-012-1915-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,14]]},"references-count":73,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["1915"],"URL":"https:\/\/doi.org\/10.1007\/s00192-012-1915-8","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"value":"0937-3462","type":"print"},{"value":"1433-3023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,14]]}}}